KBD is characterized by the degeneration of articular cartilage between joints (osteoarthritis) that can result in joint deformities and dwarfism in the most severe forms of the disease
They have not been evaluated or approved to prevent, diagnose, treat, mitigate, or cure any disease, medical condition, or ailment
7A), and discussions started to spike closer to 2021 (Fig
25, 2024 The Lancet, Trajectory of weight regain after cessation of GLP-1 receptor agonists: a systematic review and nonlinear meta-regression, March 2026 UCHealth, Many people using GLP-1 weight loss drugs may not be eating enough nutritious food, May 19, 2025 UCLA Health, Rapid weight loss can lead to loss of muscle mass, May 1, 2024 University of Colorado, The Underappreciated Benefits of GLP-1 Receptor Agonists, Nov
In the sensitivity analyses, the primary outcome analysis was repeated for the PP sample, defined as participants who followed the study protocol with full adherence, attending all study visits with no substantial interruptions in treatment as monitored from the drug dose diary